Dietary fatty acids in metabolic syndrome, diabetes and cardiovascular diseases

Current Diabetes Reviews

Volumn 8, Issue 1, 2012, Pages 2-17

  Cascio, Giuseppe ^a   Schiera, Gabriella ^a   di Liegro, Italia ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Coronary heart disease (CHD); Fatty acids; FFA dependent cell apoptosis; Insulin resistance; Metabolic syndrome; Signaling fatty acids; Type 2 diabetes

Indexed keywords

CELL NUCLEUS RECEPTOR; LEUKOTRIENE; LIGAND; LINOLEIC ACID; LIPOXIN; MONOUNSATURATED FATTY ACID; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN; THROMBOXANE; TOLL LIKE RECEPTOR 4;

APOPTOSIS; ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CELL STRESS; DRUG MECHANISM; FAT INTAKE; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PREVALENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CORONARY DISEASE; DIABETIC ANGIOPATHIES; DIET; DIETARY FATS; FATTY ACIDS; FEMALE; HUMANS; HYDROGENATION; INSULIN RESISTANCE; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTORS; TRANS FATTY ACIDS;

EID: 84855882461     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912798829241     Document Type: Article

References (247)

1. Eisenberg D, Duffy AJ, Bell RL. Update on obesity surgery. World J Gastroenterol 2006; 12: 3196-203.
2. Wild SH, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Response to Rathman and Giani. Diabetes Care 2004; 27: 2569-70.
3. Muoio DM, Newgard CB. Obesity-related derangements in metabolic regulation. Annu Rev Biochem 2006; 75: 367-401.
4. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: An overview of the epidemiological evidence. World J Gastroenterol 2011; 17: 3377-89.
5. Keys A, Menotti A, Karvonen MJ, et al. The diet and 15-year death rate in the Seven Countries Study. Am J Epidemiol 1986; 124: 903-15.
6. Pietinen P, Vartiainen E, Seppänen R, Aro A, Puska P. Changes in diet in Finland from 1972 to 1992: impact on coronary heart disease risk. Prev Med 1996; 25: 243-50.
7. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981; 2: 1303-10.
8. Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 2009; 77: 937-46.
9. Tarrago-Trani MT, Phillips KM, Lemar LE, Holden JM. New and existing oils and fats used in products with reduced trans-fatty acid content. J Am Diet Assoc 2006; 106: 867-80.
10. Gómez-Cortés P, Tyburczy C, Brenna JT, Juárez M, de la Fuent MA. Characterization of cis-9 Trans-11 Trans-15 C18:3 in milk fat by Gas Chromatography and Covalent Adduct Chemical Ionization Tandem Mass Spectrometry. J Lipid Res 2009; 50: 2412-20.
11. Wolff RL, Precht D, Molkentin J. Occurrence and distribution profiles of trans-18:1 acids in edible fats of natural origin. In: Trans fatty acids in human nutrition; Sebedio JL, Christie WW, Dundee, eds. UK: The Oily Press 1998; pp. 1-33.
12. Tyburczy C, Major C, Lock AL, et al. Individual trans octadecanoic acids and partially hydrogenated vegetable oil differentially affect hepatic lipid and lipoprotein metabolism in golden Syrian hamsters. J Nutr 2009; 139: 257-63.
13. Lemaitre RN, King IB, Mazaffarian D, Sootodehnia N, Siscovick DS. Trans-fatty acids and sudden cardiac death Atherosclerosis 2006; 7: 13-5.
14. Micha R, Mozaffarian D. Trans fatty acids: effects on cardiometabolic health and implications for policy. Prostaglandins, Leukot Essent Fatty Acids 2008; 79: 147-52.
15. Wandall B. The controversy over trans fatty acids: effects early in life. Food and Chem Toxicol 2008; 46: 3571-9.
16. Mondal K, Lalvani SB. A second order model for the catalytictransfer hydrogenation of edible oils. J Am Oil Chemist Soc 2000; 77: 1-8.
17. King JW, Holliday RL, List GR, Snyder JM. Hydrogenation of vegetable oils using mixtures of supercritical carbon dioxide and hydrogen. J Am Oil Chemist Soc 2001; 78: 107-13.
18. Wright AJ, Wong A, Diosady LL. Ni catalyst promotion of a cisselective Pd catalyst for canola oil hydrogenation. Food Res Int 2003; 36: 1069-72.
19. Fick GN. Genetics and breeding of sunflower. J Am Oil Chem Soc 1983; 60: 1252-3.
20. Liu Q, Singh S, Green A. High-oleic and high-stearic cottonseed oils: nutritionally improved cooking oils developed using gene silencing. J Am Coll Nutr 2002; 21: 205S-11S.
21. Kris-Etherton PM, Etherton TD. The impact of the changing fatty acid profile of fats on diet assessment and health. J Food Comp Analysis 2003; 16: 373-8.
22. Flickinger BD, Huth PJ. Dietary fats and oils: technologies for improving cardiovascular health. Curr Atheroscler Rep 2004; 6: 468-76.
23. Nikkari T, Luukkainen P, Pietinen P, Puska P. Fatty acid composition of serum lipid fractions in relation to gender and quality of dietary fat. Ann Med 1995; 27: 491-8.
24. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003; 14: 15-9.
25. Erkkilä A, de Mello VDF, Risérus U, Laaksonen DE. Dietary fatty acids and cardiovascular disease: an epidemiological approach. Progress in Lipid Res 2008; 47: 172-87.
26. Fernández San Juan PM. Fatty acid composition of commercial spanish fast food and snack food. J Food Comp Anal 2000; 13: 275-81.
27. Niot I, Poirier H, Tran TT, Besnard P. Intestinal absorption of longchain fatty acids: evidence and uncertainties. Progr Lipid Res 2009; 48: 101-15.
28. Hunter JE. Studies on effects of dietary fatty acids as related to their position on triglycerides. Lipids 2001; 36: 655-68.
29. Mu H, Porsgaard T. The metabolism of structured triacylglycerols. Progr Lipid Res 2005; 44: 430-48.
30. Stremmel W, Pohl L, Ring A, Herrman T. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 2001; 36: 981-9.
31. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease. NAFLD Progr Lipid Res 2009; 48: 1-26.
32. Stremmel W, Lotz G, Strohmeyer G, Berk PD. Identification, isolation, and partial characterization of a fatty acid binding protein from rat jejunal microvillous membranes. J Clin Invest 1985; 75: 1068-76.
33. Abumrad NA, El-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem 1993; 268: 17665-8.
34. Schäffer JE, Lodish HF. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell 1994; 79: 427-36.
35. Razani B, Combs TP, Wang XB, et al. Caveolin-1 deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 2002; 277: 8635-47.
36. Pol A, Martin S, Fernandez MA et al. Dynamic and regulated association of caveolin with lipid bodies: modulation of lipid body motility and function by a dominant negative mutant. Mol Biol Cell 2004; 15: 99-110.
37. Febbraio M, Silverstein RL. CD36: implications in cardiovascular disease. Int J Biochem Cell Biol 2007; 39: 2012-30.
38. Febbraio M, Abumrad NA, Sharma K, Cheng W, Pearce SF, Silverstein RL. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999; 274: 19055-62.
39. Luiken JJFP, Arumugam Y, Dyck DJ, et al. Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem 2001; 276: 40567-73.
40. Koonen DPY, Jacobs RL, Febbraio M, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with dietinduced obesity. Diabetes 2007; 56: 2863-71.
41. Coe NR, Bernlohr DA. Physiological properties and functions of intracellular fatty acid-binding proteins. Biochim Biophys Acta 1998; 1391: 287-306.
42. Makowski L, Hotamisligil GS. Fatty acid binding proteins-the evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004; 134: 2464S-8S.
43. Richieri GV, Ogata RT, Zimmerman AW, Veekamp JH, Kleinfeld AM. Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry 2000; 39: 7197-204.
44. Smith AJ, Thompson BR, Sanders MA, Bernlohr DA. Interaction of the adipocyte fatty acid-binding protein with the hormonesensitive lipase: regulation by fatty acids and phosphorylation. J Biol Chem 2007; 282: 32424-32.
45. Storch J, McDermott L. Structural and functional analysis of fatty acid-binding proteins. J Lipid Res 2009; 50: S126-31.
46. Feng L, Hatten ME, Heintz N. Brain lipid-binding protein BLBP: a novel signaling system in the developing mammalian CNS. Neuron 1994; 12: 895-908.
47. Mita R, Coles JE, Glubrecht DD, Sung R, Sun X, Godbout R. BFABP-expressing radial glial cells: the malignant glioma cell of origin? Neoplasia 2007; 9: 734-44.
48. Knudsen J, Neergaard TB, Gaigg B, Jensen MV, Hansen JK. Role of acyl-CoA binding protein in acyl-CoA metabolism and acyl-CoA-mediated cell signalling. J Nutr 2000; 130: 294S-8S.
49. Mandrup S, Sorensen RV, Helledie T, et al. Inhibition of 3T3-L1 adipocyte differentiation by expression of Acyl-CoA-binding protein antisense RNA. J Biol Chem 1998; 273: 23897-903.
50. Knudsen J, Jensen MV, Hansen JK, Faergeman NJ, Neergaard TB, Gaigg B. Role of acyl-CoA binding protein in acyl-CoA transport, metabolism and cell signalling. Mol Cell Biochem 1999; 192: 95-103.
51. Helledie T, Antonius M, Sorensen RV, et al. Lipid-binding proteins modulate ligand-dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm. J Lipid Res 2000; 41: 1740-51.
52. Nugteren DH. The enzymic chain elongation of fatty acids by ratliver microsomes. Biochim Biophys Acta 1965; 106: 280-90.
53. Jakobsson A, Westerberg R, Jacobsson A. Fatty acid elongases in mammals: their regulation and roles in metabolism. Progr Lip Res 2006; 45: 237-49.
54. Denic V, Weissman JS. A molecular caliper mechanism for determining very long-chain fatty acid length. Cell 2007; 130: 663-77.
55. Riezman H. The long and short of fatty acid synthesis. Cell 2007; 130: 587-8.
56. Tvrdik P, Asadi A, Kozak LP, Nedergaard J, Cannon B, Jacobsson A. Cig30, a mouse member of a novel membrane protein gene family, is involved in the recruitment of brown adipose tissue. J Biol Chem 1997; 272: 31738-46.
57. Kitazawa H, Miyamoto Y, Shimamura K, Nagumo A, Tokita S. Development of a high-density assay for long-chain fatty acyl-CoA elongases. Lipids 2009; 44: 765-73.
58. Takahashi T, Nagase T, Sasaki T, et al. Synthesis and evaluation of a novel indoledione class of long chain fatty acid elongase 6 ELOVL6 inhibitors. J Med Chem 2009; 52: 3142-45.
59. Ofman R, Dijkstra IME, van Roermund CWT, et al. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Mol Med 2010; 2: 90-7.
60. Tinoco J. Dietary requirements and functions of alpha-linolenic acid in animals. Prog Lipid Res 1982; 21: 1-45.
61. Holman RT. Control of polyunsaturated acids in tissue lipids. J Am Coll Nutr 1986; 5: 183-211.
62. Sprecher H, Luthria D, Mohammed S, Baykousheva P. Reevaluation of the pathway for the biosynthesis of polyunsaturated fatty acids. J Lipid Res 1995; 36: 2471-7.
63. Moore SA, Hurt E, Yoder E, Sprecher H, Spector AA. Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid. J Lipid Res 1995; 36: 2433-43.
64. Cho HP, Nakamura MT, Clarke SD. Cloning, expression, and nutritional regulation of the mammalian D-6-desaturase. J Biol Chem 1999a; 274: 471-7.
65. Cho HP, Nakamura MT, Clarke SD. Cloning, expression, and fatty acid regulation of the human D-5-desaturase. J Biol Chem 1999b; 274: 37335-9.
66. Aki T, Shimada Y, Inagaki K, et al. Molecular cloning and functional characterization of rat delta-6 fatty acid desaturase. Biochem Biophys Res Commun 1999; 255: 575-9.
67. Marquardt A, Stohr H, White K, Weber BHF. cDNA cloning, genomic structure and chromosomal localization of three members of the human fatty acid desaturase family. Genomics 2000; 66: 175-83.
68. Williard DE, Nwankwo JO, Kaduce TL, et al. Identification of a fatty acid D6-desaturase deficiency in human skin fibroblasts. J Lipid Res 2001; 42: 501-8.
69. Flowers MT, Ntambi JM. Stearoyl-CoA desaturase and its relation to high-carbohydrate diets and obesity. Biochim Biophys Acta 2009; 1791: 85-91.
70. Miyazaki M, Kim YC, Ntambi JM. A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J Lipid Res 2001; 42: 1018-24.
71. Ntambi JM, Miyazaki M, Stoehr JP, et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A 2002; 99: 11482-6.
72. Miyazaki M, Sampath H, Liu X, et al. Stearoyl-CoA desaturase 1 deficiency attenuates obesity and insulin resistance in leptinresistant mice. Biochim Biophys Res Commun 2009; 380: 818-22.
73. Kenworthy A. Peering inside lipid rafts and caveolae. Trends Biochem Sci 2002; 27: 435-8.
74. Wisniewska A, Draus J, Subczynski WK. Is a fluid-mosaic model of biological membranes fully relevant? Studies on lipid organization in model and biological membranes. Cell Mol Biol Lett 2003; 8: 147-59.
75. Fan J, Sammalkorpi M, Haataja M. Domain formation in the plasma membrane: roles of nonequilibrium lipid transport and membrane proteins. Phys Rev Lett 2008; 100.178102.
76. Simons K and Vaz WL. Model systems, lipid rafts and cell membranes. Annu Rev Biophys Biomol Struct 2004; 33: 269-95.
77. Sonnino S, Prinetti A. Sphingolipids and membrane environments for caveolin. FEBS Lett 2009; 583: 597-606.
78. Ahmed SN, Brown DA, London E. On the origin of sphingomyelin/ cholesterol-rich detergent-insoluble cell membranes: physiological concentrations of cholesterol and sphingolipid induce formation of a detergent-insoluble, liquid ordered lipid phase in model membranes. Biochemistry 1997; 36: 10944-53.
79. Brown DA, London E. Structure of detergent-resistant membrane domains: does phase separation occur in biological membranes? Biochem Biophys Res Commun 1997; 240: 1-7.
80. Brown DA, London E. Structure and function of sphingolipid-and cholesterol-rich membrane rafts. J Biol Chem 2000; 275: 17221-24.
81. Palade GE Fine structure of blood capillaries. J Appl Phys 1953; 24: 1424-36.
82. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol 1955; 1: 445-58.
83. Parton RG, Richards AA. Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic 2003; 4: 724-38.
84. Glenny JR jr, Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci USA 1992; 89: 10517-21.
85. Rothberg KG, Heuser JH, Donzell WC, Ying YS, Glenny JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell 1992; 68: 2401-8.
86. Williams TM, Lisanti MP. The caveolin proteins. Genome Biol 2004; 5: 214.
87. Fielding CJ, Fielding PE. Cholesterol and caveolae: structural and functional relationships. Biochim Biophys Acta 2000; 1529: 210-22.
88. Ikonen E, Heino S, Lusa S. Caveolins and membrane cholesterol. Biochem Soc Trans 2004; 32: 121-3.
89. Murata M, Peränen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci U S A 1995; 92: 10339-43.
90. Li S, Song KS, Lisanti MP. Expression and characterization of recombinant caveolin. Purification by polyhistidine tagging and cholesterol-dependent incorporation into defined lipid membranes. J Biol Chem 1996; 271: 568-73.
91. Thiele C, Hannah MJ, Fahrenholz F, Huttner WB. Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat Cell Biol 2000; 2: 42-9.
92. Uittenbogaard A, Smart EJ. Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae. J Biol Chem 2000; 275: 25595-9.
93. Uittenbogaard A, Everson WV, Matveev SV, Smart EJ. Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolin-annexin II lipid-protein complex. J Biol Chem 2002; 277: 4925-31.
94. Kien CL. Dietary interventions for metabolic syndrome: role of modifying dietary fats. Curr Diab Rep 2009; 9: 43-50.
95. Burns CP, Lutteneger DG, Dudley DT, GR, Spector AA. Effect of modification of plasma membrane fatty acid composition on fluidity and methotrexate transport in L1210 murine leukaemia cells. Cancer Res 1979; 39:1726-32.
96. Leekumjorn S, Wu Y, Sum AK, Chan C. Experimental and computational studies investigating trehalose protection of HepG2 cells from palmitate-induced toxicity. Biophys J 2008; 94: 2869-83.
97. Yang X, Chan C. Repression of PKR mediates palmitate-induced apoptosis in HepG2 cells through Bcl-2. Cell Res 2009; 19: 469-86.
98. Langner M, Hui S. Effect of free fatty acids on the permeability of 1,2-dimyristoyl-sn-glycero-3-phosphocholine bilayer at the main phase transition. Biochim Biophys Acta 2000; 1463: 439-47.
99. Rogerson ML, Robinson BH, Bucak S, Walde P. Kinetic studies of the interaction of fatty acids with phosphatidylcholine vesicles liposomes. Colloids Surf B Biointerfaces 2006; 48: 24-34.
100. Leekumjorn S, Cho HJ, Wu Y, Wright NT, Sum AK, Chan C. The role of fatty acids unsaturation in minimizing biophysical changes on the structure and local effects of bilayer membranes. Biochim Biophys Acta 2009; 1788: 1508-16.
101. Hyvönen MT, Oorni K, Kovanen PT, Ala-Korpela M. Changes in a phospholipids bilayer induced by the hydrolysis by a phospholipase A2 enzyme: a molecular dynamics simulation study. Biophys J 2001; 80: 565-78.
102. Roach C, Feller SE, Ward JA, Shaikh SR, Zerouga M, Stillwell W. Comparison of cis and trans fatty acid containing phosphatidylcholines on membrane properties. Biochemistry 2004; 43: 6344-51.
103. Wassall SR, Stillwell W. Docosahexaenoic acid domains: the ultimate non-rafts membrane domain. Chem Phys Lipids 2008; 153: 57-63.
104. Dratz EA, Van Breemen JF, Kamps KM, Keegstra W, Van Bruggen EF. Two-dimensional crystallization of bovine rhodopsin. Biochim Biophys Acta 1985; 832: 337-42.
105. 2H nuclear magnetic resonance order parameter profiles suggest a change of molecular shape for phosphatidylcholines containing a polyunsaturated acyl chain. Biophys J 1995; 68: 2396-403.
106. Salem N jr, Niebylski CD. The nervous system has an absolute molecular species requirement for proper function. Mol Membr Biol 1995; 12: 131-4.
107. Holte LL, Separovic F, Gawrisch K. Nuclear magnetic resonance investigation of hydrocarbon chain packing in bilayers of polyunsaturated phospholipids. Lipids 1996; 31: S199-203.
108. Gawrisch K, Holte LL. NMR investigations of non-lamellar phase promoters in the lamellar phase state. Chem Phys Lipids 1996; 81: 105-16.
109. 17O NMR. Biophys J 1997; 73: 855-64.
110. Kafrawy O, Zerouga M, Stillwell W, Jenski LJ. Docosahexaenoic acid in phosphatidylcholine mediates cytotoxicity more effectively than other omega-3 and omega-6 fatty acids. Cancer Lett 1998; 132: 23-9.
111. 31P NMR. Biochem Biophys Res Commun 2001; 286: 758-63.
112. Armstrong VT, Brzustowicz MR, Wassall SR, Jenski LJ, Stillwell W. Rapid flip-flop in polyunsaturated docosahexaenoate phospholipid membranes. Arch Biochem Biophys 2003; 414: 74-82.
113. Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 2003; 126: 1-27.
114. Feller SE. Acyl chain conformations in phospholipid bilayers: a comparative study of docosahexaenoic acid and saturated fatty acids. Chem Phys Lipids 2008; 153: 76-80.
115. Wassall SR, Brzustowicz MR, Shaikh SR, Cherezov V, Caffrey M, Stillwell W. Order from disorder, corralling cholesterol with chaotic lipids. The role of polyunsaturated lipids in membrane raft formation. Chem Phys Lipids 2004; 132: 79-88.
116. Duraisamy Y, Lambert D, O'Neill CA, Padfield PJ. Differential incorporation of docosahexaenoic acid into distinct cholesterol-rich membrane raft domain. Biochem Biophys Res Commun 2007; 360: 885-90.
117. Liang X, Nazarian A, Erdjument-Bromage H, Bornmann W, Tempst P, Resh MD. Heterogeneous fatty acylation of Src family kinases with polyunsaturated fatty acids regulates raft localization and signal transduction. J Biol Chem 2001; 276: 30987-94.
118. Webb Y, Hermida-Matsumoto L, Resh MD. Inhibition of protein palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids. J Biol Chem 2000; 275: 261-70.
119. Stulnig TM, Huber J, Leitinger N, et al. Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by altering raft lipid composition. J Biol Chem 2001; 276: 37335-40.
120. Zeyda M, Staffler G, Horejsi V, Waldhausl W, Stulnig TM. LAT displacement from lipid rafts as a molecular mechanism for the inhibition of T cell signaling by polyunsaturated fatty acids. J Biol Chem 2002; 277: 28418-23.
121. Ma DW, Seo J, Davidson LA, et al. n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. FASEB J 2004; 18: 1040-2.
122. Ebina M, Futai E, Tanabe C, Sasagawa N, Kiso Y, Ishiura S. Inhibition by KMI-574 leads to dislocation of BACE1from lipid rafts. J Neurosci Res 2009; 87: 360-8.
123. Das UN. Essential fatty acids-a review. Curr Pharm Biotechnol 2006; 7: 467-82.
124. Mukherjee S, Tessema M, Wandinger-Ness A. Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res 2006; 98: 743-56.
125. Devaux PF, Herrmann A, Ohlwein N, Kozlov MM. How lipid flippases can modulate membrane structure. Biochim Biophys Acta 2008; 1778:1591-600.
126. Schlame M, Rua D, Greenberg ML. The biosynthesis and functional role of cardiolipin. Progr Lipid Res 2000; 39: 257-88.
127. Houtkooper RH, Vaz FM. Cardiolipin, the heart of mitochondrial metabolism. Cell Mol Life Sci 2008; 65: 2493-506.
128. Paradies G, Ruggiero FM, Petrosillo G, Quagliariello E. Agedependent decline in the cytochrome c oxidase activity in rat heart mitochondria: role of cardiolipin. FEBS Lett 1997; 406: 136-8.
129. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 2007; 292: C33-44.
130. Petrosillo G, Portincasa P, Grattagliano I, et al. Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin. Biochim Biophys Acta 2007; 1767: 1260-7.
131. Hardy S, El-Assaad W, Przybytkowski E, Joly E, Prentki M, Langelier Y. Saturated fatty acid-induced apoptosis in MDA-MB-231 breast cancer cells. A role for cardiolipin. J Biol Chem 2003; 278: 31861-70.
132. Berridge MJ. Inositol trisphosphate and diacylglycerol as second messengers. Biochem J 1984; 220: 345-60.
133. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-96.
134. Nagao K, Yanagita T. Bioactive lipids in metabolic syndrome. Progr Lipid Res 2008; 47: 127-46.
135. Timmers S, Schrauwen P, de Vogel J. Muscular diacylglycerol metabolism and insulin resistance. Physiol Beh 2008; 94: 242-51.
136. Harizi H, Corcuff JB, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 2008; 14: 461-9.
137. Francois H, Coffman TM. Prostanoids and blood pressure: which way is up? J Clin Invest 2004; 114: 757-9.
138. Luo M, Flamand N, Brock TG. Metabolism of arachidonic acid to eicosanoids within the nucleus. Biochim Biophys Acta 2006; 1761: 618-25.
139. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and pro-resolving lipid mediators and pathways. Annu Rev Immunol 2007; 25: 101-37.
140. Nauta AJ, Engels F, Knippels LM, Garssen J, Nijkamp FP, Redegeld FA. Mechanisms of allergy and asthma. Eur J Pharmacol 2008; 585: 354-60.
141. Wanga J, Uedaa N. Biology of endocannabinoid synthesis system. Prostaglandins Lipids Med 2009; 89: 112-9.
142. Pérez-Chacón G, Astudillo AM, Balgoma D, Balboa MA, Balsinde J. Control of free arachidonic acid levels by phospholipases A2 and lysophospholipid acyltransferases. Biochim Biophys Acta 2009; 1791: 1103-13.
143. Pérez R, Melero R, Balboa MA, Balsinde J. Role of group VIA calcium-independent phospholipase A2 in arachidonic acid release, phospholipids fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide. J Biol Chem 2004; 279: 40385-91.
144. Huwiler A, Pfeilschifter J. Lipids as targets for novel antiinflammatory therapies. Pharmacol Ther 2009; 124: 96-112.
145. Cowart LA. Sphingolipids: players in the pathology of metabolic disease. Trends Endocrinol Metab 2009; 20: 34-42.
146. Bragt MCE, Popeijus HE. Peroxisome proliferators-activated receptors and the metabolic syndrome. Physiol Behav 2008; 94: 187-97.
147. Alaynick WA. Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion 2008; 8: 329-37.
148. Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004; 10: 1245-50.
149. Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113: 159-70.
150. Hevener AL, He W, Barak Y, et al. Muscle-specific PPARg deletion causes insulin resistance. Nat Med 2003; 9: 1491-7.
151. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferators-activated receptors α and δ. Proc Natl Acad Sci USA 1997; 94: 4312-7.
152. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995; 83: 813-9.
153. Zhang B, Graziano MP, Doebber TW, et al. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 1996; 271: 9455-9.
154. Krey G, Braissant O, L'Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997; 11: 779-91.
155. Hirasawa A, Hara T, Katsuma S, Adachi T, Tsujimoto G. Free fatty acid receptors and drug discovery. Biol Pharm Bull 2008; 31: 1847-51.
156. Civelli O. GPCR deorphanizations: the novel, the known and the unexpected transmitters. Trends Pharmacol Sci 2005; 26: 15-9.
157. Xiong Y, Miyamoto N, Shibata K, et al. Short-chain fatty acids stimulate leptin production in adipocytes through the G proteincoupled receptor GPR41. Proc Natl Acad Sci U S A 2004; 101: 1045-50.
158. Hara T, Hirasawa A, Ichimura A, Kimura I, Tsujimoto G. Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J Pharm Sci 2011; 100: 3594-601.
159. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003; 422: 173-6.
160. Leren P. The Oslo diet-heart study. Eleven-year report. Circulation 1970; 42: 935-42.
161. Keys A, Menotti A, Aravanis C, et al. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med 1984; 13: 141-54.
162. Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in greenland eskimos. In: Advanced Nutrition Reserach; Draper HH eds. New York: Plenum Press 1980; vol. 3: pp 1-22.
163. Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Acta Med Scand 1980; 208: 401-6.
164. Baghurst KI, Baghurst PA, Record SJ. Demographic and dietary profiles of high and low fat consumers in Australia. J Epidemiol Community Health 1994; 48: 26-32.
165. Nakamura T, Azuma A, Kuribayashi T, Sugihara H, Okuda S, Nakagawa M. Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the Kumihama study. Br J Nutr 2003; 89: 267-72.
166. Sauer LA, Blask DE, Dauchy RT. Dietary factors and metabolism in experimental tumors. J Nutr Biochem 2007; 18: 637-49.
167. Kato I, Majumdar AP, Land SJ, Barnholtz-Sloan JS, Severson RK. Dietary fatty acids, luminal modifiers, and risk of colorectal cancer. Int J Cancer 2010; 127: 942-51.
168. Kagawa Y, Nishizawa M, Suzuki M, et al. Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. J Nutr Sci Vitaminol 1982; 28: 441-53.
169. Gibson RA. Australian fish an excellent source of both arachidonic acid and omega-3 polyunsaturated fatty acids. Lipids 1983; 78: 743-52.
170. Ma J, Folsom AR, Shahar E, Eckfeldt JH. Plasma fatty acid composition as an indicator of habitual dietary fat intake in middleaged adults. The Atherosclerosis Risk in Communities ARIC Study investigators. Am J Clin Nutr 1995; 62: 564-71.
171. Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Akabane M, Tsugane S. Single measurement of serum phospholipid fatty acid as a biomarker of specific fatty acid intake. Eur J Clin Nutr 2001; 55: 643-50.
172. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferatoractivated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006; 45: 120-59.
173. Zoete V, Grosdidier A, Michielin O. Peroxisome proliferatoractivated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 2007; 1771: 915-25.
174. Carrol KK and Khor HT. Dietary fat in relation to tumorigenesis. Progr Biochem Pharmacol 1975; 10: 308-53.
175. Grundy SM. Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. New En J Med 1986; 314: 745-8.
176. Kris-Etherton PM, Pearson TA, Wan Y, et al. Highmonounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr 1999; 70: 1009-15.
177. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins: a meta-analysis of 27 trials. Arterioscler Thromb 1992; 12: 911-9.
178. Gang A, Grundy SM and Koffler M. Effect of high carbohydrate intake on hyper-glycemia, islet cell function and plasma lipoproteins in NIDDM. Diabetes Care 1992; 15: 1572-80.
179. Paniagua JA, Gallego de la Sacristana A, Romero I, et al. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007; 30: 1717-23.
180. Gillingham LG, Harris-Janz S, and Jones PJH. Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids 2011; 46: 209-28.
181. Goldbourt U, Yaari S, Medalie JH. Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology 1993; 82: 100-21.
182. Ascherio A. Epidemiologic studies on dietary fats and coronary heart disease. Am J Med 2002; 113: 9-12.
183. Iso H, Sato S, Umemura U, et al. Linoleic acid, other fatty acids and the risk of stroke. Stroke 2002; 33: 2086-93.
184. Charnock JS, Sundram K, Abeywardena MY, McLennan PL, Tan DT. Dietary fats and oils in cardiac arrhythmia in rats. Am J Clin Nutr 1991; 53: 1047S-9S.
185. Lovejoy J, Di Girolamo M. Habitual Dietary Intake and insulin sensitivity in lean and obese adults. Am J Clin Nutr 1992; 55: 1174-9.
186. Salmerón J, Hu FB, Manson JM, et al. Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 2001; 73: 1019-26.
187. Pelikánová T, Kazdová L, Chvojková S, Base J. Serum phospholipid fatty acid composition and insulin action in type 2 diabetic patients. Metabolism 2001; 50: 1472-8.
188. Williams CM, Burdge G. Long chain n-3 PUFA: plant v. marine sources. Proc Nutr Soc 2006; 65: 42-50.
189. Mozaffarian D, Ascherio A, Hu FB, et al. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 2005; 111: 157-64.
190. Albert CM, Oh K, Whang W, et al. Dietary alpha-linolenic acid intake and risk of sudden cardiac death and coronary heart disease. Circulation 2005; 112: 3232-8.
191. He K, Song Y, Daviglus ML, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of
192. Van Horn L, McCoin M, Kris-Etherton PM, et al. the evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 2008; 108: 287-331.
193. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials. Am J Med 2002; 112: 298-304.
194. Harris W, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008; 197: 12-24.
195. Risérus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Progr Lipid Res 2009; 48: 44-51.
196. Pan DA, Lillioja S, Milner MR, et al. Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J Clin Invest 1995: 96: 2802-8.
197. Summmers LK, Fielding BA, Bradshaw HA, et al. Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. Diabetologia 2002; 45: 369-77.
198. Wang H, Storlien LH, Huang XF. Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am J Physiol Endocrinol Metab 2002; 282: E1352-9.
199. De Caterina R, Madonna R, Schmidt EB. n-3 fatty acids in the treatment of diabetic patients. Diabetes Care 2007; 30: 1012-26.
200. Hu FB, Manson JE, Willett WC. Types of dietary fat and risk of coronary heart disease: a critical review. J Am Coll Nutr 2001; 20: 5-19.
201. Temme EH, Mensink RP, Hornstra G. Comparison of the effects of diets enriched in lauric, palmitic, or oleic acids on serum lipids and lipoproteins in healthy women and men. Am J Clin Nutr 1996; 63: 897-903.
202. Van de Laar F, van de Lisdonk E, Lucassen P, et al. Fat intake in patients newly diagnosed with type 2 diabetes: a 4-year follow-up study in general practice. Br J Gen Pract 2004; 54: 177-82.
203. Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010; 39: 504-18.
204. Tsuji H, Kasai M, Takeuchi H, Nakamura M, Okazaki M, Kondo K. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind, controlled trial in healthy men and women. J Nutr 2001; 131: 2853-59.
205. Han JR, Deng B, Sun J, et al. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects. Metabolism 2007; 56: 985-91.
206. Astrup A, Dyerberg J, Elwood P, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr 2011; 93: 684-8.
207. Nestel P, Noakes N, Belling B. Plasma lipoproteins and Lpa changes with substitution of elaidic acid for oleic acid in the diet. J Lip Res 1992; 33: 1029-36.
208. Katan MB. Trans fatty acids and plasma lipoproteins. Nutr Rev 2000; 58: 188-91.
209. Stender S, Dyerberg J, Bysted A, Leth T, Astrup A. High levels of industrially produced trans fat in popular fast foods. N Engl J Med 2006; 354: 1650-2.
210. Stender S, Dyerberg J, Astrup A. Fast food:. Unfriendly and unhealthy. Int J Obes 2007; 31: 887-90.
211. Astrup A, Dyerberg J, Selleck M, Stender S. Nutrition transition and its relationship to the development of obesity and related chronic diseases. Obes Rev 2008; 9 Suppl. 1: 48-52.
212. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr 2009; 63: S5-21.
213. Kavanagh K, Jones KL, Sawyer J, et al. Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. Obesity 2007; 15: 1675-84.
214. Bendsen NT, Haugaard SB, Larsen TM, Chabanova E, Stender S, Astrup A. Effect of trans-fatty acid intake on insulin sensitivity and intramuscolar lipids-a randomized trial in overweight postmenopausal women. Metabolism 2011; 60: 906-913.
215. Esmaillzadeh A, Azadbakht L. Different kinds of vegetable oils in relation to individual cardiovascular risk factors among Iranian women. Br J Nutr 2011; 105: 919-27.
216. Clandinin MT, Cheema S, Field CJ, Garg ML, Venkatraman J, Clandinin TR. Dietary fat: exogenous determination of membrane structure and cell function. Faseb J 1991; 5: 2761-9.
217. Weidmann P, De Courten M, Bohlen L. Insulin resistance, hyperinsulinemia and hypertension. J Hypert 1993; 11: S27-38.
218. Smit LA, Willett WC and Campos H. Trans-fatty acid isomers in adipose tissue have divergent associations with adiposity in humans. Lipids 2010; 45: 693-700.
219. Mozaffarian D, Cao H, King IB, et al. Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study. Ann Intern Med 2010; 21: 153: 790-9.
220. De Caterina R. n-3 fatty acids in cardiovascular disease. New Engl J Med 2011; 364: 2439-50.
221. Lee S, Gura KM, Kim S, Arsenault DA, Bistrian BR, Puder M. Current clinical applications of omega-6 and omega-3 fatty acids. Nutr Clin Pract 2006; 21: 323-41.
222. McCarty M. Dietary saturate/unsaturate ratio as a determinant of adiposity. Med Hypoth 2010; 75:14-6.
223. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
224. Zraika S, Dunlop M, Proietto J, Andrikopoulos S. Effects of free fatty acids on insulin secretion in obesity. Obes Rev 2002; 3: 103-12.
225. Haber EP, Ximenes HM, Procópio J, Carvalho CR, Curi R, Carpinelli AR. Pleiotropic effects of fatty acids on pancreatic betacells. J Cell Physiol 2003; 194: 1-12.
226. Yaney GC, Corkey BE. Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 2003; 46: 1297-312.
227. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-10.
228. Cnop M, Ladriere L, Hekerman P, et al. Selective inhibition of eukaryotic translation initiation factor 2a dephosphorylation potentiates fatty acid-induced endoplasmic reticulum stress and causes pancreatic b-cell dysfunction and apoptosis. J Biol Chem 2007; 282: 3989-97.
229. Yuan H, Zhang X, Huang X, et al. NADPH oxidase 2-derived reactive oxygen species mediate FFAs-induced dysfunction and apoptosis of b-cells via JNK, p38 MAPK and p53 pathways. PLoS One 2010; 5: 1-9.
230. Kavamori D, Kaneto H, Nakatani Y, et al. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem 2006; 281: 1091-8.
231. Martinez SC, Tanabe K, Cras-Méneur C, Abumrad NA, Bernal-Mizrachi E, Permutt MA. Inhibition of Foxo1 protects pancreatic islet β-cells against fatty acid and endoplasmic reticulum stressinduced apoptosis. Diabetes 2008; 57: 846-59.
232. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 9047-54.
233. Srinivasan S, Ohsugi M, Liu Z, Fatrai S, Bernal-Mizrachi E, Permutt MA. Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3{beta} in mouse insulinoma cells. Diabetes 2005; 54: 968-75.
234. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-61.
235. Nguyen MT, Satoh H, Favelyukis S, et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005; 280: 35361-71.
236. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 2008; 29: 381-402.
237. Holland WL, Bikman B, Wang LP, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 2011; 121: 1858-70.
238. Zhou Y-T, Shimabukuro M, Wang M-Y, et al. Role of peroxisome proliferator-activated receptor a in disease of pancreatic b cells. Proc Natl Acad Sci USA 1998; 95: 8898-903.
239. Dubois M, Paltou F, Kerr-Conte J, et al. Expression of peroxisome proliferator-activated receptor g in the normal human pancreatic islet cells. Diabetologia 2000; 43: 1165-9.
240. Hellemans KH, Hannaert J-C, Denys B, et al. Susceptibility of pancreatic beta cells to fatty acids is regulated by LXR/PPARadependent stearoyl-Coenzyme A desaturase. PLoS One 2009; 4: e7266.
241. Fatehi-Hassanabad Z, Chan CB. Expression of PPARa modifies fatty acid effects on isulin secretion in uncoupling protein-2 knockout mice. Nutrition & Metabolism 2007; 4:6.
242. Němcová-Fürstová V, James RF, Kovář J. Inhibitory effect of unsaturated fatty acids on saturated fatty acid-induced apoptosis in human pancreatic hh-cells: activation of caspases and ER stress induction. Cell Physiol Biochem 2011; 27: 525-38.
243. Yeop Han C, Kargi AY, Omer M, et al. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. Diabetes 2010; 59: 386-96.
244. Qi D, Cai K, Wang O, et al. Fatty acids induce amylin expression and secretion by pancreatic beta-cells. Am J Physiol Endocrinol Metab. 2010; 298: E99-E107.
245. Schiera G, Proia P, Alberti C, Mineo M, Savettieri G, Di Liegro I. Neurons produce FGF2 and VEGF and secrete them at least in part by shedding extracellular vesicles. J Cell Mol Med 2007; 11: 1384-94.
246. Proia P, Schiera G, Mineo M, et al. Astrocytes shed extracellular vesicles that contain fibroblast growth factor-2 and vascular endothelial growth factor. Int J Mol Med 2008; 21: 63-7.
247. Antonyak MA, Li B, Boroughs LK, et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA 2011; 108: 4852-7.